NCT04722003View on ClinicalTrials.gov

Mucosal Immunity Against Neisseria Gonorrhoeae After 4CMenB Vaccination

PHASE2CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

November 1, 2021

Primary Completion Date

October 2, 2023

Study Completion Date

October 2, 2023

Conditions
Gonorrhoea
Interventions
BIOLOGICAL

Meningococcal Group B Vaccine

A combination vaccine consisting of recombinant proteins Neisserial adhesin A (NadA), Neisserial Heparin Binding Antigen (NHBA), and factor H binding protein (fHbp), Outer Membrane Vesicles (OMV), aluminum hydroxide, sodium chloride, histidine, and sucrose.

OTHER

Placebo

0.9% Sodium Chloride, USP injection.

Trial Locations (1)

30030-1705

The Hope Clinic of Emory University, Decatur

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT04722003 - Mucosal Immunity Against Neisseria Gonorrhoeae After 4CMenB Vaccination | Biotech Hunter | Biotech Hunter